Catheter Precision (NYSEAMERICAN:VTAK) Stock Price Down 16.8% – What’s Next?

Catheter Precision, Inc. (NYSEAMERICAN:VTAK) traded down 16.8% on Thursday . The company traded as low as $1.03 and last traded at $1.14. 4,810,220 shares traded hands during mid-day trading, a decline of 76% from the average session volume of 20,025,498 shares. The stock had previously closed at $1.37.

Catheter Precision Price Performance

The company has a debt-to-equity ratio of 0.35, a current ratio of 0.06 and a quick ratio of 0.06. The firm has a market capitalization of $4.12 million, a PE ratio of -0.09 and a beta of -1.07. The company has a 50-day moving average price of $0.93 and a 200-day moving average price of $1.33.

Catheter Precision (NYSEAMERICAN:VTAK) last posted its quarterly earnings data on Monday, May 18th. The company reported ($1.39) EPS for the quarter, topping analysts’ consensus estimates of ($20.90) by $19.51. Catheter Precision had a negative return on equity of 76.51% and a negative net margin of 1,297.56%.The firm had revenue of $0.43 million during the quarter, compared to analysts’ expectations of $1.60 million.

Institutional Investors Weigh In On Catheter Precision

A hedge fund recently bought a new stake in Catheter Precision stock. Millennium Management LLC purchased a new position in shares of Catheter Precision, Inc. (NYSEAMERICAN:VTAK) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 34,721 shares of the company’s stock, valued at approximately $64,000. Millennium Management LLC owned approximately 2.08% of Catheter Precision at the end of the most recent reporting period. 20.34% of the stock is currently owned by institutional investors and hedge funds.

Catheter Precision Company Profile

Catheter Precision, Inc (NYSE American: VTAK) is a medical device company specializing in the design, development and manufacture of catheter-based products for interventional cardiology and peripheral vascular procedures. The company’s core business centers on balloon catheter platforms, offering both standard and specialty catheter configurations that address applications ranging from percutaneous transluminal angioplasty (PTA) to percutaneous transluminal coronary angioplasty (PTCA). Catheter Precision’s product portfolio is engineered to meet diverse clinical needs, including high-pressure dilation, scored and cutting balloon therapies, and drug-coated balloon delivery.

All of Catheter Precision’s products are developed in its ISO 13485-certified, FDA-registered manufacturing facility in Bloomington, Minnesota.